TNFRSF9 and Familial prostate cancer: By 10 years, 33% of cases with high levels of both TNFRSF9 and PTN died of prostate cancer compared to only 5% of cases with low levels of one or both of these proteins (Fig. 7c), highlighting the utility of these blood markers for risk stratification of AA prostate cancer patients.